Chien R.-N.Peng C.-Y.JIA-HORNG KAOHu T.-H.Lin C.-C.Hu C.-T.Chen C.-Y.Hsieh T.-Y.Lin H.-C.Chuang W.-L.2021-09-042021-09-0420140815-9319https://www.scopus.com/inward/record.uri?eid=2-s2.0-84897607632&doi=10.1111%2fjgh.12416&partnerID=40&md5=3f4defb36088a136ef763ee8e427d3fehttps://scholars.lib.ntu.edu.tw/handle/123456789/581989Background and Aims: Oral nucleos(t)ide analogs (NAs) are effective in suppressing hepatitis B virus (HBV) replication in treatment na?ve chronic hepatitis B (CHB) patients. However, little is known about the treatment modification and adherence on such patients with prolonged NA treatment. Methods: In this multicenter observational study, a total of 600 NA-na?ve Taiwanese CHB patients aged 16 years and older were enrolled. The 600 patients were retrospectively identified by their NA treatment history from August 2008 to July 2009; this cohort was prospectively followed up over 3 years. During the 3-year period, incidence of treatment modifications, reasons for modification, and rate of adherence were evaluated. Results: Among the 583 evaluable patients, the initial NA treatment included entecavir (ETV) in 468 patients, telbivudine (LdT) in 67, and lamivudine (LVD) in 48. During the 3-year treatment, 9.0% of ETV-treated patients, 38.8% of LdT-treated patients, and 54.2% of LVD-treated patients had treatment modification. The main reasons for treatment modification were fulfilling stopping criteria in the ETV group (40.5%) and virological breakthrough in both the LdT (61.5%) and LVD (46.2%) groups. The proportion of patients with adherence rate (>90%) at year 3 was 90.8% in the ETV group, 83.9% in the LdT group, and 83.9% in the LVD group. Conclusions: Treatment-na?ve CHB patients with a 3-year ETV treatment in Taiwan have the lower likelihood of treatment modification and better rate of adherence compared with those with LdT or LVD treatment. ? 2013 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd.Chronic hepatitis B; Entecavir; Lamivudine; Patient adherence; Telbivudine[SDGs]SDG3entecavir; lamivudine; telbivudine; virus DNA; adolescent; adult; aged; article; chronic hepatitis; demography; drug efficacy; female; follow up; hepatitis B; Hepatitis B virus; human; incidence; long term care; maintenance therapy; major clinical study; male; middle aged; observational study; patient compliance; priority journal; Taiwan; treatment modification; treatment outcome; treatment refusal; unspecified side effect; very elderly; young adult; chronic hepatitis B; entecavir; lamivudine; patient adherence; telbivudine; Administration, Oral; Adolescent; Adult; Antiviral Agents; Cohort Studies; Dihydropyridines; Female; Follow-Up Studies; Guanine; Hepatitis B; Humans; Lamivudine; Male; Middle Aged; Patient Compliance; Prospective Studies; Taiwan; Time Factors; Young Adultjournal article10.1111/jgh.12416243549952-s2.0-84897607632